Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sintilimab in Resected Esophageal Squamous Cell Carcinoma
NCT06161909Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Union Hospital. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06161909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161909.